Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention
JAMA Neurology · 01.06.2026 · 83 (6) · 521
DOI: 10.1001/jamaneurol.2026.0832 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Neurology, erschienen am 01.06.2026. Verfasst von Theresa M Harrison und 21 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Berkeley. Hauptthemen laut MEDLINE: Brain, Cognition, Cognitive Dysfunction, Cognitive Enhancement. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Importance Brain imaging biomarkers may (1) identify underlying mechanisms of intervention effects and (2) define brain characteristics of those most likely to benefit cognitively from the intervention.
Objective
To test whether (1) a lifestyle intervention is related to brain changes, (2) brain changes are correlated with intervention-specific cognition changes, and (3) brain imaging biomarkers provide information about who is likely to benefit from a lifestyle intervention. Design, Setting, and Participants In this randomized clinical trial, the POINTER Imaging study was an ancillary study of the 2-year, single-blind multicenter US POINTER clinical trial in which neuroimaging data were collected on eligible enrolled participants. The study was conducted from May 2019 to March 2023 (final follow-up, May 14, 2025). Participants were enrolled into the POINTER Imaging study following a standard procedure at 5 clinical sites in the US. Participant eligibility criteria included an age of 60 to 79 years, sedentary lifestyle, and suboptimal diet, plus at least 2 additional risk criteria for cognitive decline and no contraindications for neuroimaging.
Interventions
Participants were randomly assigned to receive the structured or self-guided intervention. Both interventions emphasized increased physical and cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring, but they differed in intensity and accountability. Main Outcomes and Measures There were 4 primary imaging outcomes: global β-amyloid (Aβ) burden, tau burden in the entorhinal cortex (ERC), hippocampal (HC) volume, and white matter hyperintensity volume. The primary cognitive measure was a global cognitive composite.
Results
Among 1943 parent trial participants who were assessed for eligibility, 983 underwent at least 1 magnetic resonance imaging or positron emission tomography scanning session. The mean (SD) age was 68.4 (5.2) years; 605 participants (61.5%) were female and 378 male (38.5%). Five hundred sixteen participants received the structured intervention and 467 the self-guided intervention. There were no intervention group differences in longitudinal cognitive or imaging outcomes. Intervention group differences were not associated with or moderated by Aβ status or accumulation. There was a negative association between change in ERC tau and change in global cognition in the self-guided group that was attenuated in the structured group (difference in association: 0.289; 95% CI, 0.029 to 0.550; interaction P = .03). Lower baseline HC volume was associated with greater cognitive benefit for participants in the structured group vs the self-guided group (lower HC: 0.077 SD; 95% CI, 0.022 to 0.132; higher HC: 0.002 SD; 95% CI, −0.037 to 0.041; interaction P = .03). Conclusion and Relevance This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. Trial Registration ClinicalTrials.gov Identifier: NCT03688126
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, Berkeley.
- University of California, Davis.
- Wake Forest University School of Medicine, Winston-Salem, North Carolina.
- Brigham and Women's Hospital, Boston, Massachusetts.
- University of Southern California, Los Angeles.
- University of Michigan, Ann Arbor.
Förderung
- NIA NIH HHS
Zitieren
APA
Harrison, T. M., Harvey, D. J., Chadwick, T., Chao, Y., Taggett, J., Maillard, P., Lovato, L., Farias, S. T., Papp, K. V., Lockhart, S. N., Toga, A. W., Koeppe, R. A., Jung, Y., Jagust, W. J., Whitmer, R. A., Snyder, H. M., Carrillo, M. C., Baker, L. D., Espeland, M. A., …, & Landau, S. M. (2026). Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention. JAMA Neurology, 83(6), 521. https://doi.org/10.1001/jamaneurol.2026.0832
Vancouver
Harrison TM, Harvey DJ, Chadwick T, Chao Y, Taggett J, Maillard P, et al. Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention. JAMA Neurology. 2026;83(6):521. doi:10.1001/jamaneurol.2026.0832
BibTeX
@article{Harrison2026,
author = {Harrison, Theresa M and Harvey, Danielle J and Chadwick, Trevor and Chao, Yishu and Taggett, Jacinda and Maillard, Pauline and Lovato, Laura and Farias, Sarah Tomaszewski and Papp, Kathryn V and Lockhart, Samuel N and Toga, Arthur W and Koeppe, Robert A and Jung, Youngkyoo and Jagust, William J and Whitmer, Rachel A and Snyder, Heather M and Carrillo, Maria C and Baker, Laura D and Espeland, Mark A and Vemuri, Prashanthi and DeCarli, Charles and Landau, Susan M},
title = {Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention},
journal = {JAMA Neurology},
year = {2026},
volume = {83},
number = {6},
pages = {521},
doi = {10.1001/jamaneurol.2026.0832}
}
EUVIMED